ClinicalTrials.gov
ClinicalTrials.gov Menu

iPSC Neurons From Adult Survivors of Childhood Cancer Who Have Persistent Vincristine-Induced Neuropathy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02564484
Recruitment Status : Recruiting
First Posted : September 30, 2015
Last Update Posted : March 1, 2018
Sponsor:
Collaborators:
University of Chicago
National Cancer Institute (NCI)
Information provided by (Responsible Party):
St. Jude Children's Research Hospital

Brief Summary:

This observational study is designed to establish induced pluripotent stem cells (iPSCs) from childhood cancer survivors who did or did not develop persistent treatment-induced peripheral neuropathy, from which to make human neurons for comparing their sensitivity to vincristine and other potentially neurotoxic drugs.

Investigators will assess the effects of inherited genome variations on treatment-induced peripheral neuropathy that persists in adults who were cured of childhood cancer. Cells from childhood cancer survivors who did or did not develop drug-induced neuropathy will be isolated and induced to become neurons. Cell sensitivity to anticancer agents will be tested in both groups and compared to determine if the survivors have genetic variants that correspond to those identified in companion genomic studies. This will assist in determining if gene variants increase the risk of treatment-induced neurotoxicity.

The investigators are interested in detecting changes of phenotype pre-post treatment in each group (cases, controls) respectively, as well in comparing the pre-post treatment phenotypic changes between the two groups (cases vs. controls).


Condition or disease
Leukemia Lymphoma

Detailed Description:

Participants will be recruited from an existing protocol at St. Jude (SJLIFE, NCT00760656). Complete neuropathic evaluations are obtained as part of SJLIFE, and the information will be shared for use in the SJLPSC study. A one-time blood draw will be obtained, and peripheral blood mononuclear cells (PBMC's) will be isolated for eventual creation of induced pluripotent stem cells (iPSC) that will be differentiated into human neurons. These human neurons will allow the investigators to functionally validate and further interrogate CEP72 genetic variants or variants in other genes that are associated with persistent (or acute) vincristine neuropathy using a "state of the art" cellular model of human neurons. Furthermore, creating neurons from patients at the extremes (highly sensitive to vincristine-induced neuropathy and matched controls) allows the study of differences at baseline and after treatment with vincristine.

PRIMARY OBJECTIVE:

  • To establish induced pluripotent stem cells (iPSCs) from childhood cancer survivors who did or did not develop persistent treatment-induced peripheral neuropathy, from which to make human neurons to assess their sensitivity to vincristine and determine whether neurons from patients who developed neuropathy are more sensitive to vincristine or other neurotoxic chemotherapy.

SECONDARY OBJECTIVE:

  • To evaluate the iPSC neurons made from patients with persistent treatment-related neuropathy and iPSC neurons from patients who did not develop neuropathy from the same treatment, for phenotypic difference prior to and after exposure to vincristine or other potentially neurotoxic medications.

Study Type : Observational
Estimated Enrollment : 200 participants
Observational Model: Case-Control
Time Perspective: Prospective
Official Title: Collection of PBMC's From Patients With Unusually Severe Vincristine-Induced Neuropathy for the Creation of Neuronal-Like Cells
Actual Study Start Date : February 8, 2016
Estimated Primary Completion Date : February 2020
Estimated Study Completion Date : February 2023

Resource links provided by the National Library of Medicine


Group/Cohort
Neuropathy
Adult survivors who developed persistent treatment-related neuropathy.
Control
Adult survivors who did not develop persistent treatment-related neuropathy.



Primary Outcome Measures :
  1. Number of participants for whom iPSCs were created [ Time Frame: Up to 6 months after participant enrollment ]
    Blood will be drawn on Day 1, processed and sent to the University of Chicago for infectious diseases testing and creation of PBMCs for eventual development of iPS cells.


Secondary Outcome Measures :
  1. Phenotype differences [ Time Frame: Up to 6 months after participant enrollment ]
    Cell phenotypes of the iPSC neurons made from each patient (case or control) will be observed before and after treatment of neurotoxic drugs, giving for each drug a pair of observations from a patient.


Biospecimen Retention:   Samples With DNA
Blood samples will be obtained from each cohort.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Cases and controls for this study will be recruited from among the acute lymphocytic leukemia (ALL) survivor members of the St. Jude Lifetime Cohort study (SJLIFE). Cases will be matched for gender, tumor type, estimated cumulative vincristine dose at which toxicity occurred, intended vincristine chemotherapy regimen, age (within 5 years) and race with existing controls.
Criteria

Inclusion Criteria - Neuropathy Patients:

  • Adult survivor of childhood ALL
  • Presence of any neuromotor, neurocortical, or neurocerebellar toxicity after vincristine treatment (either acute and/or persistent neuropathy)
  • At least 50% of the persistent vincristine neuropathy cases will have the CEP72 promoter variant (rs924607) or a coding variant in CEP72 that is predicted to be damaging (CADD score >9). The balance of neuropathy cases will either have variants in other genes that are associated with vincristine neuropathy identified in the ongoing genome-wide association study (GWAS) of 1250 St. Jude Life ALL survivors, or have neuropathy in the absence of known genetic variants altering the risk of neuropathy.
  • Patient understands the nature of the study and provides informed consent

Inclusion Criteria - Controls:

  • Adult survivor of childhood diagnosis of ALL
  • Absence of persistent neurotoxicity (grade 0) after completion of a standard vincristine-containing chemotherapy regimen (may or may not have experience acute neuropathy during treatment.
  • Matched to a specified subject with neurotoxicity based on age (within 5 years), tumor type, chemotherapy regimen or total vincristine dosage, race and ethnicity.
  • At least 50% of the controls will have the CEP72 promoter variant T/T genotype (at rs924607) or a coding variant in CEP72 that is predicted to be damaging (CADD score >9). The balance of controls will either have variants in other genes that are associated with vincristine neuropathy identified in the ongoing GWAS of 1250 St. Jude Life ALL survivors, or will not have a known genetic variant altering the risk of neuropathy.
  • Patient understands the nature of the study and provides informed consent

Inclusion of Women and Minorities:

  • Individuals of both genders, all races and ethnic groups are eligible for this protocol.

Exclusion Criteria - Both Cohorts:

  • Treatment with other severely neurotoxic chemotherapy (i.e. cisplatin) prior to or concomitantly with vincristine. Carboplatin therapy is allowed
  • Presence of peripheral neuropathy prior to vincristine therapy
  • Poorly controlled or insulin-dependent diabetes or other condition likely to predispose to neurotoxicity

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02564484


Contacts
Contact: William E. Evans, PharmD 866-278-5833 referralinfo@stjude.org

Locations
United States, Tennessee
St. Jude Children's Research Hospital Recruiting
Memphis, Tennessee, United States, 38105
Contact: William E Evans, Pharm.D    866-278-5833    referralinfo@stjude.org   
Principal Investigator: William E Evans, Pharm.D         
Sponsors and Collaborators
St. Jude Children's Research Hospital
University of Chicago
National Cancer Institute (NCI)
Investigators
Principal Investigator: William E. Evans, PharmD St. Jude Children Research Hospital

Additional Information:
Responsible Party: St. Jude Children's Research Hospital
ClinicalTrials.gov Identifier: NCT02564484     History of Changes
Other Study ID Numbers: SJLPSC
R01CA036401 ( U.S. NIH Grant/Contract )
First Posted: September 30, 2015    Key Record Dates
Last Update Posted: March 1, 2018
Last Verified: February 2018

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by St. Jude Children's Research Hospital:
Cancer Therapy
Pharmacogenomics
Drug Response
Genetic Variants
Vincristine-Induced Neuropathy
Cancer Survivor

Additional relevant MeSH terms:
Vincristine
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action